[Form 4] Genvor Inc Insider Trading Activity

Rhea-AI Filing Summary

Genvor Inc. reporting person Chad Lee Pawlak Sr. — who is listed as Chief Executive Officer, a Director and a 10% owner — received 250,000 shares of common stock on 10/08/2025 as a non-derivative acquisition. After the award, Pawlak beneficially owns 6,250,000 shares. The filing states the shares were a compensation award for July–September 2025, under a restructured package the board approved on 12/20/2024. The Form 4 is signed and dated 10/09/2025. No exercise prices, derivative transactions, cash values, or additional plan terms are disclosed in this filing.

Positive

• Board‑approved compensation issued (award tied to a board action on 12/20/2024)
• Direct equity grant (non‑derivative shares rather than options) of 250,000 shares

Negative

• Material insider award increases CEO beneficial ownership to 6,250,000 shares without disclosed vesting or valuation
• No dilution context provided — the filing does not state total outstanding shares or plan share pool, limiting investor assessment of impact

Insights

Corporate Governance Analyst

TL;DR: Chief executive received a board‑approved compensation grant of 250,000 shares, increasing his stake to 6.25M shares.

The grant is presented as a routine compensation award linked to the July–September 2025 period and tied to a restructured package approved by the board on 12/20/2024. As reported, this is a direct issuance of common stock rather than an option or convertible instrument.

The key dependencies are the disclosed board approval and the stated period for the award; the filing does not disclose vesting terms, share valuation, or the dilutive impact on outstanding shares. Investors can track potential effects on share count only if additional filings disclose plan details or aggregate outstanding shares.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pawlak Chad Lee Sr.

(Last) (First) (Middle)

1550 W HORIZON RIDGE PKWY

STE R #3040

(Street)

HENDERSON NV 89012

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Genvor Inc [ GNVR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

3. Date of Earliest Transaction (Month/Day/Year)
10/08/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/08/2025		A		250,000	A	(1)	6,250,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Compensation award for July-September of 2025, pursuant to restructured compensation package approved by the Company's Board of Directors as of December 20, 2024.

	/s/ Chad Pawlak	10/09/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Genvor insider Chad Pawlak (GNVR) receive on 10/08/2025?

He received a non‑derivative grant of 250,000 common shares, reported on 10/08/2025 with the Form 4 signed 10/09/2025.

How many Genvor shares does Chad Pawlak beneficially own after this transaction?

The filing reports beneficial ownership of 6,250,000 shares following the award.

Why was the 250,000‑share award granted to the CEO?

The filing states it is a compensation award for July–September 2025 under a restructured compensation package approved by the board on 12/20/2024.

Does the Form 4 disclose vesting terms or cash value for the award?

No. The Form 4 discloses the number of shares and the reason but does not provide vesting terms, price, or cash valuation.

Was this issuance a derivative transaction or an option exercise?

No. The award is listed in Table I as a non‑derivative common stock acquisition, and Table II shows no derivative transactions.